Risultati ricerca pubblicazioni

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-re

pubblicato su: EUROPEAN JOURNAL OF CANCER - 2020

Cortellini A., Bersanelli M., Santini D., Buti S., Tiseo M., Cannita K., Perrone F., Giusti R., De Tursi M., Zoratto F., Marconcini R., Russano M., Zeppola T., Anesi C., Filetti M., Marchetti P., Botticelli A., Gelibter A., De Galitiis F., Vitale M. G., Rastelli F., Tudini M., Silva R. R., Atzori F., Chiari R., Ricciuti B., De Giglio A., Migliorino M. R., Mallardo D., Vanella V., Mosillo C., Bracarda S., Rinaldi S., Berardi R., Natoli C., Ficorella C., Porzio G., Ascierto P. A.

Ricerc@Sapienza

Risultati ricerca pubblicazioni

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-re

Use of nivolumab in elderly patients with advanced squamous non–small-cell lung cancer: results from the Italian cohort of an expanded access programme